Friday - May 01, 2026

Category Archives: Marketing & Sales

Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma

The Key Gastroparesis Companies in the market include – CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others. DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034″ … Continue reading →

Flowave Emerges From Stealth To Build The Agentic Infrastructure Layer For Performance-Based Advertising

The company’s autonomous AI system delivers qualified consumer actions to advertisers through organic distribution at a fraction of legacy CPM costs — replacing the outdated playbook of paid media, manual optimization, and middlemen. Flowave, Inc., a Venice, CA-based performance infrastructure … Continue reading →

Graves’ Ophthalmopathy Market Forecast Analysis 2034: Clinical Trial, Pipeline, FDA Approvals and companies by DelveInsight

Graves’ Ophthalmopathy Market Graves Ophthalmopathy companies Include Novartis, Harbour BioMed, Viridian Therapeutics, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sling Therapeutics, ValenzaBio, Argenx, HanAll Biopharma, Immunovant Sciences, Novartis, Viridian Therapeutics And Many Others The Graves’ Ophthalmopathy (Thyroid Eye Disease) market was valued … Continue reading →

Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Duchenne Muscular Dystrophy pipeline constitutes 75+ key companies continuously working towards developing 75+ Duchenne Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Lewy Body Dementia Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lewy Body Dementia pipeline constitutes key companies continuously working towards developing Lewy Body Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Psoriasis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis

The Key Psoriasis Companies in the market include – UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others.   DelveInsight’s … Continue reading →

Non-Alcoholic Steatohepatitis Pipeline Set for Transformational Expansion by 2026 with 75+ Therapies, Strong Clinical Momentum from Novo Nordisk, Viking Therapeutics, Inventiva Pharma | DelveInsight

Non-Alcoholic Steatohepatitis Clinical Trial Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering a pivotal phase of innovation and clinical acceleration, driven by … Continue reading →

STAT Inhibitors Pipeline Set for Breakthrough Innovation by 2026 with 22+ Therapies and Expanding Clinical Momentum | DelveInsight

STAT Inhibitors Clinical Trials Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others The STAT inhibitors therapeutic landscape is undergoing a significant transformation, … Continue reading →

Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ Therapies and Robust Clinical Advancements | DelveInsight

Diabetic Neuropathy Clinical Trial Leading diabetic neuropathy companies include Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., AlgoTherapeutix, Tris Pharma, Inc., JMackem Co., Ltd, Lexicon Pharmaceuticals, Merz Pharmaceuticals GmbH, and others are evaluating new diabetic neuropathy drugs to improve the … Continue reading →

Acute on Chronic Liver Failure Pipeline Set for Strategic Expansion by 2026 with Emerging Gene Therapies and Novel Mechanisms from Genfit and Gyre Therapeutics | DelveInsight

Acute on Chronic Liver Failure Clinical Trial The Acute on Chronic Liver Failure therapeutic pipeline is witnessing a gradual but significant evolution, driven by increasing understanding of disease mechanisms and unmet clinical needs. The pipeline is currently composed of 5+ … Continue reading →